Pelvic congestion syndrome is a condition that causes pain in the pelvic region. This pain occurs mostly due to problems in the veins near the pelvic area. Pelvic congestion syndrome is a common gynecological condition in women that leads to often severe chronic pelvic pain. The causes of pelvic congestion syndrome generally involves pelvic inflammatory disease, endometriosis, pelvic varicosities and other conditions. Mostly in hospitals, pelvic congestion syndrome diagnosis is generally performed by venography. Prior to venogram, a pelvic ultrasound or other imaging study is performed to check any abnormalities.
According to a study reported in 2016, it is estimated that 10 million women suffer from pelvic congestion syndrome with approximately 7 million women avoid seeking treatment. Worldwide prevalence of chronic pelvic pain is estimated to vary from 26.6% in Egypt and 5.7% in Austria. The economic scenario of the pelvic congestion syndrome has a great impact.
Download a Sample Copy of This Report: –https://www.factmr.com/connectus/sample?flag=S&rep_id=3127?PJ
Pelvic Congestion Syndrome Treatment Market: Key Players
Some of the key players present across the value chain of the global pelvic congestion syndrome treatment market are Sanofi, TOLMAR Inc., Actiza Pharmaceuticals, Pfizer, Debio RP, AbbVie Inc, AstraZeneca, Novartis Pharmaceuticals Corporation, Indivior Inc., Pernix Ireland Pain Limited, ALZA Corporation, Fresenius Kabi USA,LLC
What Do You Get in a Fact.MR Study?
- Factors affecting the overall development of the global Pelvic Congestion Syndrome Treatment Market
- Factor that might restrain the growth of the global market in the coming years of the forecast period.
- What is present competitive scenario of the global Pelvic Congestion Syndrome Treatment Market and its intricate details concerning potential business prospects of leading market players
- Pricing strategies of several different market players in the global Pelvic Congestion Syndrome Treatment Market
Pelvic Congestion Syndrome Treatment Market: Segmentation
The global pelvic congestion syndrome treatment market is segmented by disease type, medication and distributional channel.
- Segmentation by Disease Type
- Primary Pelvic Congestion Syndrome Treatment
- Secondary Pelvic Congestion Syndrome Treatment
- Segmentation by Medication
- NSAIDs (nonsteroidal anti-inflammatory drugs) Pelvic Congestion Syndrome Treatment
- Psychotherapy Pelvic Congestion Syndrome Treatment
- Analgesics Pelvic Congestion Syndrome Treatment
- Dihydroergotamine
- Progestins
- Others
- Segmentation by Distributional Channel
- Hospital
- Diagnostics laboratories
- Gynecology Clinics
- Ambulatory Surgical Centers
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Brazil, Mexico, Argentina, Chile, Peru, Rest of LATAM)
- EU – (Germany, France, Italy, Spain), UK, BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
- CIS & Russia
- Japan
- Asia Pacific Excluding Japan (Greater China, India, S. Korea, ASEAN Countries, Rest of APEJ)
How Fact.MR Assists in Making Strategic Moves?
The data provided in the Pelvic Congestion Syndrome Treatment Market report offers comprehensive analysis of important industry trends. Industry players can use this data to strategize their potential business moves and gain remarkable revenues in the upcoming period.
The report covers the price trend analysis and value chain analysis along with analysis of diverse offering by market players. The main motive of this report is to assist enterprises to make data-driven decisions and strategize their business moves.
Customize this report for your specific research solution:https://www.factmr.com/connectus/sample?flag=RC&rep_id=3127?PJ
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : [email protected]